FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2891044561> ?p ?o ?g. }

• W2891044561 endingPage "326" @default.
• W2891044561 startingPage "1" @default.
• W2891044561 abstract "Background Neuroendocrine tumours (NETs) are a group of heterogeneous cancers that develop in cells in the diffuse neuroendocrine system. Objectives To estimate the clinical effectiveness of three interventions [everolimus (Afinitor ® ; Novartis International AG, Basel, Switzerland), lutetium-177 DOTATATE (177Lu-DOTATATE) (Lutathera ® ; Imaging Equipment Ltd, Radstock, UK) and sunitinib (Sutent ® ; Pfizer Inc., New York, NY, USA)] for treating unresectable or metastatic NETs with disease progression and establish the cost-effectiveness of these interventions. Data sources The following databases were searched from inception to May 2016: MEDLINE, MEDLINE In-Process & Other Non-Indexed Citations, MEDLINE Daily, Epub Ahead of Print, EMBASE, Cochrane Central Register of Controlled Trials and Web of Science. Review methods We systematically reviewed the clinical effectiveness and cost-effectiveness literature on everolimus, 177Lu-DOTATATE and sunitinib for treating advanced, unresectable or metastatic progressive NETs. The following NET locations were considered separately: pancreas, gastrointestinal (GI) tract and lung, and GI tract (midgut only). We wrote a survival partition cohort-based economic evaluation in Microsoft Excel ® 2013 (Microsoft Corporation, Redmond, WA, USA) from the UK NHS and Personal Social Services perspective. This comprised three health states: (1) progression-free survival (PFS), (2) progressed disease and (3) death. Results Three randomised controlled trials (RCTs), RADIANT-3 [RAD001 in Advanced Neuroendocrine Tumors, Third Trial; pancreatic NETs (pNETs): everolimus vs. best supportive care (BSC)], A6181111 (pNETs: sunitinib vs. BSC) and RADIANT-4 (RAD001 in Advanced Neuroendocrine Tumors, Fourth Trial; GI and lung NETs: everolimus vs. BSC), met the inclusion criteria for the clinical effectiveness systematic review. The risk of bias was low. Although the NETTER-1 (Neuroendocrine Tumors Therapy) RCT, of 177Lu-DOTATATE plus 30 mg of octreotide (Sandostatin ® , Novartis) compared with 60 mg of octreotide, was excluded from the review, we nonetheless present the results of this trial, as it informs our estimate of the cost-effectiveness of 177Lu-DOTATATE. The pNETs trials consistently found that the interventions improved PFS and overall survival (OS) compared with BSC. Our indirect comparison found no significant difference in PFS between everolimus and sunitinib. Estimates of OS gain were confounded because of high rates of treatment switching. After adjustment, our indirect comparison suggested a lower, but non-significant, hazard of death for sunitinib compared with everolimus. In GI and lung NETs, everolimus significantly improved PFS compared with BSC and showed a non-significant trend towards improved OS compared with BSC. Adverse events were more commonly reported following treatment with targeted interventions than after treatment with BSC. In the base case for pNETs, assuming list prices, we estimated incremental cost-effectiveness ratios (ICERs) for everolimus compared with BSC of £45,493 per quality-adjusted life-year (QALY) and for sunitinib compared with BSC of £20,717 per QALY. These ICERs increased substantially without the adjustment for treatment switching. For GI and lung NETs, we estimated an ICER for everolimus compared with BSC of £44,557 per QALY. For GI (midgut) NETs, the ICERs were £199,233 per QALY for everolimus compared with BSC and £62,158 per QALY for a scenario analysis comparing 177Lu-DOTATATE with BSC. We judge that no treatment meets the National Institute for Health and Care Excellence’s (NICE) end-of-life criteria, although we cannot rule out that sunitinib in the A6181111 trial does. Limitations A RCT with included comparators was not identified for 177Lu-DOTATATE. The indirect treatment comparison that our economic analysis was based on was of a simple Bucher type, unadjusted for any differences in the baseline characteristics across the two trials. Conclusions Given NICE’s current stated range of £20,000–30,000 per QALY for the cost-effectiveness threshold, based on list prices, only sunitinib might be considered good value for money in England and Wales. Future work Further analysis of individual patient data from RADIANT-3 would allow assessment of the robustness of our findings. The data were not made available to us by the company sponsoring the trial. Study registration This study is registered as PROSPERO CRD42016041303. Funding The National Institute for Health Research Health Technology Assessment programme." @default.
• W2891044561 created "2018-09-27" @default.
• W2891044561 creator A5001249792 @default.
• W2891044561 creator A5008364894 @default.
• W2891044561 creator A5009110738 @default.
• W2891044561 creator A5014526107 @default.
• W2891044561 creator A5017164838 @default.
• W2891044561 creator A5020747166 @default.
• W2891044561 creator A5033415669 @default.
• W2891044561 creator A5054440572 @default.
• W2891044561 creator A5069352430 @default.
• W2891044561 creator A5071268085 @default.
• W2891044561 creator A5081409332 @default.
• W2891044561 creator A5082727271 @default.
• W2891044561 creator A5085150977 @default.
• W2891044561 creator A5089453687 @default.
• W2891044561 date "2018-09-01" @default.
• W2891044561 modified "2023-10-16" @default.
• W2891044561 title "Everolimus, lutetium-177 DOTATATE and sunitinib for advanced, unresectable or metastatic neuroendocrine tumours with disease progression: a systematic review and cost-effectiveness analysis" @default.
• W2891044561 cites W1453000988 @default.
• W2891044561 cites W1490001593 @default.
• W2891044561 cites W1503273596 @default.
• W2891044561 cites W1575433014 @default.
• W2891044561 cites W1579772977 @default.
• W2891044561 cites W1608997557 @default.
• W2891044561 cites W1776389102 @default.
• W2891044561 cites W1790290811 @default.
• W2891044561 cites W1891914108 @default.
• W2891044561 cites W1937476324 @default.
• W2891044561 cites W1950460442 @default.
• W2891044561 cites W1964093149 @default.
• W2891044561 cites W1967665878 @default.
• W2891044561 cites W1968684826 @default.
• W2891044561 cites W1970326135 @default.
• W2891044561 cites W1970908877 @default.
• W2891044561 cites W1973230030 @default.
• W2891044561 cites W1973577894 @default.
• W2891044561 cites W1975208767 @default.
• W2891044561 cites W1981002414 @default.
• W2891044561 cites W1982967337 @default.
• W2891044561 cites W1988174589 @default.
• W2891044561 cites W1988986189 @default.
• W2891044561 cites W1990509102 @default.
• W2891044561 cites W1991175480 @default.
• W2891044561 cites W1994222210 @default.
• W2891044561 cites W2002071982 @default.
• W2891044561 cites W2003281337 @default.
• W2891044561 cites W2005295931 @default.
• W2891044561 cites W2005947177 @default.
• W2891044561 cites W2010344947 @default.
• W2891044561 cites W2012856564 @default.
• W2891044561 cites W2014811656 @default.
• W2891044561 cites W2015756811 @default.
• W2891044561 cites W2016356824 @default.
• W2891044561 cites W2018913523 @default.
• W2891044561 cites W2019911597 @default.
• W2891044561 cites W2027676394 @default.
• W2891044561 cites W2028133886 @default.
• W2891044561 cites W2037628350 @default.
• W2891044561 cites W2040135422 @default.
• W2891044561 cites W2040901964 @default.
• W2891044561 cites W2045007794 @default.
• W2891044561 cites W2046207560 @default.
• W2891044561 cites W2050083847 @default.
• W2891044561 cites W2060122062 @default.
• W2891044561 cites W2060513754 @default.
• W2891044561 cites W2062011075 @default.
• W2891044561 cites W2062907835 @default.
• W2891044561 cites W2063178653 @default.
• W2891044561 cites W2065249841 @default.
• W2891044561 cites W2066160166 @default.
• W2891044561 cites W2067691287 @default.
• W2891044561 cites W2068865024 @default.
• W2891044561 cites W2071066672 @default.
• W2891044561 cites W2072470605 @default.
• W2891044561 cites W2074731710 @default.
• W2891044561 cites W2077123274 @default.
• W2891044561 cites W2079292111 @default.
• W2891044561 cites W2081270036 @default.
• W2891044561 cites W2088019251 @default.
• W2891044561 cites W2088344186 @default.
• W2891044561 cites W2091825842 @default.
• W2891044561 cites W2092901728 @default.
• W2891044561 cites W2094993869 @default.
• W2891044561 cites W2096261897 @default.
• W2891044561 cites W2099478219 @default.
• W2891044561 cites W2100133641 @default.
• W2891044561 cites W2100283328 @default.
• W2891044561 cites W2100581885 @default.
• W2891044561 cites W2102617530 @default.
• W2891044561 cites W2105641380 @default.
• W2891044561 cites W2107276199 @default.
• W2891044561 cites W2107362494 @default.
• W2891044561 cites W2108613323 @default.
• W2891044561 cites W2110922803 @default.
• W2891044561 cites W2112268677 @default.
• W2891044561 cites W2115686439 @default.
• W2891044561 cites W2117796497 @default.

• next